Che Zhengping, Wang Wei, Zhang Lin, Lin Zhenghong
School of Life Sciences, Chongqing University, Chongqing, 401331, China.
Department of Cancer Center, Chongqing University Three Gorges Hospital, School of Medicine, Chongqing University, Chongqing, 404000, China.
J Pharm Anal. 2025 Jan;15(1):101099. doi: 10.1016/j.jpha.2024.101099. Epub 2024 Sep 12.
Gastrointestinal (GI) cancers are prevalent globally, with leading incidence and mortality rates among malignant tumors. Despite notable advancements in surgical resection, radiotherapy, and chemotherapy, the overall survival rates remain low. Hence, it is imperative to explore alternative approaches that enhance patient outcomes. Cluster of differentiation 47 (CD47), serving as an early diagnostic marker, is predominantly overexpressed in GI cancers and associated with poor prognosis. Targeting the CD47-signal regulatory protein alpha (SIRPα) signaling pathway may provide a novel strategy for GI cancers treatment. This study summarizes current knowledge of the structure and function of CD47 and SIRPα, their roles in signaling pathways, the prognostic significance of CD47, therapeutic strategies targeting the CD47-SIRPα signaling pathway in GI cancer, and highlights key issues for future investigations.
胃肠道（GI）癌症在全球范围内普遍存在，在恶性肿瘤中发病率和死亡率位居前列。尽管手术切除、放疗和化疗取得了显著进展，但总体生存率仍然很低。因此，探索能够改善患者预后的替代方法势在必行。分化簇47（CD47）作为一种早期诊断标志物，在胃肠道癌症中主要呈过表达，且与预后不良相关。靶向CD47-信号调节蛋白α（SIRPα）信号通路可能为胃肠道癌症治疗提供一种新策略。本研究总结了目前关于CD47和SIRPα的结构与功能、它们在信号通路中的作用、CD47的预后意义、针对胃肠道癌症中CD47-SIRPα信号通路的治疗策略的认识，并强调了未来研究的关键问题。
